Intellia Therapeutics (NTLA) is Initiated by Jefferies to Hold, Price Target at $33

Intellia Therapeutics (NTLA) was Initiated by Jefferies to “Hold” and the brokerage firm has set the Price Target at $33. Jefferies advised their investors in a research report released on May 31, 2016.

Many Wall Street Analysts have commented on Intellia Therapeutics. Credit Suisse Initiated Intellia Therapeutics on May 31, 2016 to “Outperform”, Price Target of the shares are set at $39.

Intellia Therapeutics

Leave a Reply

Intellia Therapeutics - Is it time to Sell?

Top Brokerage Firms are advising their investors on Intellia Therapeutics. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.